A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network

Journal of Neurology

Volumn 260, Issue 3, 2013, Pages 847-855

  Seidel, C ^a,b   Hentschel, B ^c   Simon, M ^d   Schnell, O ^e   Heese, O ^f   Tatagiba, M ^g   Krex, D ^h   Reithmeier, T ⁱ   Kowoll, A ^j   Weller, M ^k   Wick, W ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j RUHR UNIVERSITY BOCHUM   (Germany)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Bevacizumab; Deep venous thrombosis; Glioma; Intracranial hemorrhage; Stroke

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DEEP VEIN THROMBOSIS; EPIDURAL HEMATOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL;

AGED; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; CEREBROVASCULAR DISORDERS; COHORT STUDIES; FEMALE; GERMANY; GLIOMA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84876489040     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6718-9     Document Type: Article

References (29)

1. CBTRUS (2012) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 (March 23, 2012 Revision). Source: Central Brain Tumor Registry of the United States, Hinsdale, IL. www.cbtrus.org
2. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16:269-278
3. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV (1997) Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer 33:1592-1596
4. Chamberlain MC (2010) Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 116:3988-3999
5. Choucair AK, Silver P, Levin VA (1987) Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 66:357-358
6. Fadul C, Wood J, Thaler H, Galicich J, Patterson RH Jr, Posner JB (1988) Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 38:1374-1379
7. Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM (2011) Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol 105:281-289
8. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
9. Gupta A, Young RJ, Karimi S, Sood S, Zhang Z, Mo Q, Gutin PH, Holodny AI, Lassman AB (2011) Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. Am J Neuroradiol 32:1301-1306
10. Harada K, Kiya K, Matsumura S, Mori S, Uozumi T (1982) Spontaneous intracranial hemorrhage caused by oligodendroglioma-a case report and review of the literature. Neurol Med Chir (Tokyo) 22:81-84
11. Jenkins EO, Schiff D, Mackman N, Key NS (2010) Venous thromboembolism in malignant gliomas. J Thromb Haemost 8:221-227
12. Khasraw M, Holodny A, Goldlust SA, DeAngelis LM (2012) Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol 23:458-463
13. Kreisl TN, Toothaker T, Karimi S, DeAngelis LM (2008) Ischemic stroke in patients with primary brain tumors. Neurology 70:2314-2320
14. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109
15. Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89:640-646
16. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277-2285
17. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787
18. Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49:287-297
19. Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99:49-56
20. Rieger J, Bahr O, Ronellenfitsch MW, Steinbach J, Hattingen E (2010) Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia? J Clin Oncol 28:e477
21. Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Hilton M, Abrey L, Cloughesy T. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio. Neuro Oncol Abstract 2012
22. Schrader B, Barth H, Lang EW, Buhl R, Hugo HH, Biederer J, Mehdorn HM (2000) Spontaneous intracranial haematomas caused by neoplasms. Acta Neurochir (Wien) 142:979-985
23. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, Wildrick DM (1998) Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42:1044-1055
24. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH (2007) Epidemiology of venous thromboembolism in 9,489 patients with malignant glioma. J Neurosurg 106:601-608
25. Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, Pabinger I, Marosi C (2007) Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 9:89-95
26. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S (2009) Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev CD005392
27. Wakai S, Yamakawa K, Manaka S, Takakura K (1982) Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 10:437-444
28. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743-5750
29. Wick W, Kaufmann A (2006) Glioblastoma: What's ischemia got to do with it? Neurology 67:1540-1541